Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabinoid combination
- Development stage
- Preclinical
- Lead developer
- SOL Global Investments Corp.
- Modality
- Small Molecules
- Administration
- Inhalation, Oral, Sublingual, Buccal, Topical, Intranasal, Rectal, Transdermal, Intravenous, Subcutaneous, Intraperitoneal, Ophthalmic, Pulmonary
01
Overview
"Cannabinoid combination" is a proprietary drug regimen developed by Scythian Biosciences in collaboration with the University of Miami. This combination drug is being investigated in pre-clinical and clinical trials with the aim of becoming the first accepted drug regimen for the treatment of concussions and neurotrauma.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)PPAR (PPAR family)
Beyond the preview
Go deeper on cannabinoid combination.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabinoid combination.